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Abstract 
This article discusses the importance of designing vaccine products with attributes that will help to mitigate challenges that 
immunization programs are facing as they introduce new vaccines. The handling, management, and use of vaccines is becoming 
increasingly complex; placing an increased burden on health care professionals who distribute and deliver vaccines and on supply
systems that need to transport, manage, store, and track disparate products. Now is the time to influence future vaccine products
to mitigate the complexity and pave the way for success.  
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1.   Vaccine products: what will the future bring? 
The future for vaccines is bright as new vaccines wield the ability to avert additional diseases; new delivery, 
formulation, and stabilization methods improve immunization effectiveness; and new sources of funding are secured 
to ensure that those in greatest need have access to these life-saving products [1-4]. Progress in these areas should 
provide health benefits to all and financial benefits to communities and to industry.  
There are some practical, logistical, and safety concerns that accompany the many changes that developing-country
immunization programs are already experiencing as new vaccine products are being introduced. Few programs have 
the cold chain storage capacity to handle increasing volumes [5-7]. Many new vaccines will be targeted to different 
age groups than the traditional course of vaccines for infants and require new delivery strategies. For example, 
human papillomavirus (HPV) vaccine is provided to adolescent girls and is often given in schools [8]. In addition, 
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new product handling instructions continue to emerge. For example, the World Health Organization’s (WHO) multi-
dose vial policy is being updated to incorporate new product formats such as low-dose liquid vaccines without 
preservatives [9,10]. Changes to vaccine storage recommendations are also envisioned to allow for controlled 
ambient temperature storage to facilitate timely vaccination of populations living beyond the reach of the existing 
cold chain infrastructure (e.g., delivery of a dose of hepatitis B vaccine at birth), for rapid response to pandemics, 
and to free up cold chain space for less-heat-stable vaccines [4,11,12]. As we project forward a decade or two, we 
can also predict that new vaccine-delivery methods such as jet injectors, micro-needle patches, dissolvable tablets, 
sublingual gels, and nasal drops or sprays will become more available [13,14].  
The bottom line is that in the future the handling, management, and use of vaccines will become increasingly 
complex. This will place an increased burden on health care professionals who distribute and deliver vaccines and 
on supply systems that need to transport, manage, store, and track disparate products. The potential for human error 
may also increase and could result in negative health outcomes for vaccine recipients if products are stored, 
measured, reconstituted, or delivered incorrectly. Now is the time to influence future vaccine products to mitigate 
the complexity and pave the way for success. Steps are already being taken in this direction. 
2.  A generic preferred product profile for vaccines 
The Vaccine Presentation and Packaging Advisory Group (VPPAG) is working to provide practical guidance to 
vaccine manufacturers to help ensure that the public-sector market in developing countries is able to implement 
rapid and effective uptake of essential, new vaccines. The VPPAG was originally formed by the GAVI Alliance 
secretariat to address product profile issues for pneumococcal and rotavirus vaccines and has now been reinstated 
under the WHO. The group provides a unique forum for industry and public-sector dialogue on presentation and 
packaging of vaccine products. VPPAG membership includes representatives from the International Federation of 
Pharmaceutical Manufacturers’ Association; the Developing Country Vaccine Manufacturers’ Network; WHO’s 
Department of Immunization, Vaccines, and Biologicals (both the Expanded Programme on Immunization and 
Quality, Safety, and Standards teams); PATH; the United Nations Children’s Fund (UNICEF) Supply and Program 
Divisions; John Snow, Inc.; the United States Centers for Disease Control and Prevention (CDC); and the GAVI 
Alliance secretariat. 
The VPPAG recently completed a draft generic preferred product profile for new vaccines for developing countries. 
This consensus document between industry and the public sector is meant to serve as a resource for any entity 
involved in research and development of vaccines for developing-country markets.  
An overview of existing VPPAG generic recommendations for vaccines in development and the VPPAG’s ongoing 
work program in this area is provided below (Table 1). The complete document is available at 
http://sites.google.com/site/vppagp/gppp [15].  
3. Roles for vaccine developers 
The generic recommendations above and in Table 1 are meant to provide signals to vaccine developers about the 
preferences and concerns of the public-sector, developing-country markets. These include preferences for products 
with smaller overall volumes, products and packaging made of materials that minimize environmental impact, 
products that are intuitively easy to prepare and administer, and product formats that minimize the possibility for 
human error. Many of these attributes are likely also important for other, more lucrative markets. Private physicians’ 
offices in industrialized countries often use small, domestic refrigerators to store vaccines and therefore experience 
cold chain capacity issues [16]. Nurses and pharmacists in the United States and Europe will also be impacted by the 
increasing number of vaccines and complexity of product formats and delivery routes. If a vaccine product can be 
created that will serve both markets, efficiencies of scale can be achieved that should benefit all.
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Table 1. Existing VPPAG generic recommendations for new vaccines and VPPAG work program (Version 
2.1, dated 10 August 2009) 
Parameter Recommendations for 
producers and developers 
VPPAG work program to develop 
additional recommendations 
Formulation
Single- vs. multi-
component vaccines 
Provide vaccines, whenever possible, in 
“ready-to-use” presentations that do not 
require the mixing of components. 
Heat stability x Vaccines should be stable at standard 
cold chain temperatures (2° to 8°C). 
x Maximize vaccine heat stability to 
improve effectiveness and enable higher 
temperature storage. 
x Label/license products for higher 
temperature storage, whenever possible. 
1.1 Monitor and contribute to ongoing work to define 
the desirable higher temperature storage conditions 
for vaccines and add specificity to recommendations, 
as further evidence becomes available. 
1.2 Contribute to ongoing work to develop policy and 
guidelines for potential higher temperature storage of 
vaccines.  
Freeze stability Formulate vaccines so that they will not be 
damaged by freezing, where feasible.  
Antimicrobial
preservatives 
Include preservative in multi-dose vials of 
injectable vaccines, where feasible, to allow 
safe use of opened containers in subsequent 
sessions. 
Product format Provide vaccines in formats to minimize 
1) number of steps and 2) potential for error 
during preparation and administration.
Optimal number of 
doses per primary 
container 
2.1 Obtain and assess data and tools to determine if 
generic guidelines can be made with regard to optimal 
number of doses per container for new vaccines.  
2.2. Explore the need to define parameters for 
vaccines that must be used within a “short time 
frame” of preparation.  
Prefilled injection 
devices 
Vaccines in prefilled injection devices 
should have both space-saving and 
autodisabling features.
3.1 Assess country demand and willingness to pay for 
compact, prefilled autodisable devices (CPADs) for 
specific vaccines. 
3.2 Assess non-cost obstacles for use of CPADs. 
3.3 Identify solutions to minimize storage space 
required.
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Parameter Recommendations for 
producers and developers 
VPPAG work program to develop 
additional recommendations 
Labeling
Product labeling 
and package insert 
4.1 Assess potential improvements and innovations 
for product labeling and package inserts that could 
improve immunization safety and efficiency.  
4.2 Develop guidance on the optimal location and 
number of inserts in secondary or tertiary packaging 
that will meet regulatory requirements. 
Vaccine vial 
monitors (VVMs) 
Include VVMs on all vaccines, as 
recommended by WHO and UNICEF. 
Freeze indicators 5.1 Explore new options for prevention and/or 
detection of freeze damage, including licensing of 
some vaccines for storage at higher temperatures and 
use of freeze indicators on primary containers and/or 
packaging.
Visual cue 
regarding discard 
6.1 Work with the WHO and industry to explore the 
concept of placing a visual cue on primary containers 
of vaccine to identify which vials may or may not be 
kept for subsequent sessions. 
Packaging
Multi-component 
vaccines 
7.1 Assess the programmatic impact of the vial clip 
and other mechanisms for keeping vaccine 
components together. 
7.2 Develop recommendations on keeping vaccine 
components together during all or part of vaccine 
distribution and storage. 
Maximum packed 
volume
Minimize volume and weight of secondary 
and tertiary packaging, as well as the need 
for repackaging for in-country supply chain 
distribution.
8.1 Update existing WHO maximum packed volume 
recommendations and provide generic maximum 
packed volumes for different vaccine types and 
containers (e.g., liquid in vial, lyophilized in vial with 
diluent, liquid in CPAD, oral in dropper, etc.) in 
secondary packaging and grossing factors for tertiary 
packaging.
Materials, including 
the primary 
container and 
delivery device 
1. Use materials for delivery devices, 
primary containers, and secondary and 
tertiary packaging that minimize the 
environmental impact of waste disposal 
for resource-limited systems.
8.2 Consult with industry on feasible 
recommendations for packaging materials as well as 
maximum volume recommendations for primary 
containers and secondary and tertiary packaging for 
different vaccine types and containers, and advise the 
WHO on setting these as recommendations for 
prequalified vaccines. 
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The key differences between the industrialized and developing-country markets for vaccines are the latter’s lesser 
resources to pay for the products themselves and for the storage, distribution, personnel, and training to properly 
handle and administer them. While the generic recommendations provide a good sense of direction, they can only go 
so far in assisting vaccine developers. There are also product-specific considerations that need to be taken into 
account such as the deployment strategy (e.g., campaign versus outreach settings) and the innate characteristics of 
the vaccine (e.g., maximum achievable stability and production method). These considerations will impact the ideal 
product profile for the vaccine. For example, a vaccine used mostly in campaign settings may be more cost-effective 
in a multi-dose primary container, and a vaccine that must be freeze-dried to achieve adequate stability may need to 
be physically bundled with its diluent to prevent reconstitution errors. Vaccine-specific analyses of these issues will 
be required. The VPPAG can serve as resource to help gather and analyze these data and work through issues
together with industry and the public sector to reach consensus on the best product profile for a specific vaccine for 
developing-country markets. 
At present, the VPPAG is gathering data to inform a product profile for second-generation HPV vaccines. The work 
includes review of qualitative and quantitative data from immunization programs that have recently introduced first 
generation versions of HPV vaccine, temperature monitoring studies to explore the possibility of controlled ambient 
temperature storage of HPV vaccine during the last stage of distribution (e.g., from health centers to schools), and 
discussions with vaccine producers about potential new containers and temperature storage requirements for the 
vaccine.
Work on other specific product profiles will likely follow, and industry is encouraged to initiate dialogue with the 
VPPAG on specific issues and products, as helpful. 
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